Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
Top Cited Papers
Open Access
- 24 June 2013
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 166 (2), 217-223.e11
- https://doi.org/10.1016/j.ahj.2013.05.007
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Glucose handling by the kidneyKidney International, 2011
- Renal glucose reabsorption inhibitors to treat diabetesTrends in Pharmacological Sciences, 2011
- Rosiglitazone: what went wrong?BMJ, 2010
- Intensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non–Insulin-Dependent DiabetesDiabetes, 2005
- Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1971